These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19008255)

  • 1. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.
    Majithiya J; Sharp A; Parmar A; Denning DW; Warn PA
    J Antimicrob Chemother; 2009 Jan; 63(1):161-6. PubMed ID: 19008255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.
    Ghannoum MA; Okogbule-Wonodi I; Bhat N; Sanati H
    J Chemother; 1999 Feb; 11(1):34-9. PubMed ID: 10078778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Voriconazole, Isavuconazole, Fluconazole, and Anidulafungin in the Treatment of Emerging Candida auris Using an Immunocompromised Murine Model of Disseminated Candidiasis.
    Gamal A; Long L; Herrada J; Aram J; McCormick TS; Ghannoum MA
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0054921. PubMed ID: 34228541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.
    Warn PA; Sharp A; Mosquera J; Spickermann J; Schmitt-Hoffmann A; Heep M; Denning DW
    J Antimicrob Chemother; 2006 Dec; 58(6):1198-207. PubMed ID: 17071636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model.
    González GM; Portillo OJ; Uscanga GI; Andrade SE; Robledo M; Rodríguez C; Elizondo M
    J Antimicrob Chemother; 2009 Sep; 64(3):571-3. PubMed ID: 19570754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis.
    Warn PA; Morrissey J; Moore CB; Denning DW
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2664-71. PubMed ID: 10991841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voriconazole and fluconazole susceptibility of Candida isolates.
    Pelletier R; Loranger L; Marcotte H; DE Carolis E
    J Med Microbiol; 2002 Jun; 51(6):479-483. PubMed ID: 12018654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternatives to amphotericin B for Candida rugosa infection.
    Hernandez S; Gonzalez GM; McCarthy DI; Colombo AL; Najvar LK; Bocanegera R; Graybill JR
    J Antimicrob Chemother; 2004 Aug; 54(2):477-80. PubMed ID: 15215225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of triazoles in a murine disseminated infection by Candida krusei.
    Mariné M; Pastor FJ; Serena C; Guarro J
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3585-8. PubMed ID: 19470509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.
    Karyotakis NC; Dignani MC; Anaissie EJ
    Antimicrob Agents Chemother; 1995 Mar; 39(3):775-7. PubMed ID: 7793892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile.
    Scorzoni L; de Lucas MP; Mesa-Arango AC; Fusco-Almeida AM; Lozano E; Cuenca-Estrella M; Mendes-Giannini MJ; Zaragoza O
    PLoS One; 2013; 8(3):e60047. PubMed ID: 23555877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice.
    Graybill JR; Najvar LK; Holmberg JD; Luther MF
    Antimicrob Agents Chemother; 1995 Apr; 39(4):924-9. PubMed ID: 7785997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.
    Warn PA; Sharp A; Morrissey G; Denning DW
    J Antimicrob Chemother; 2005 Sep; 56(3):590-3. PubMed ID: 16046462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
    Astvad KMT; Hare RK; Arendrup MC
    Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.
    Lepak AJ; Marchillo K; VanHecker J; Diekema D; Andes DR
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5642-8. PubMed ID: 24002092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
    Kullberg BJ; Sobel JD; Ruhnke M; Pappas PG; Viscoli C; Rex JH; Cleary JD; Rubinstein E; Church LW; Brown JM; Schlamm HT; Oborska IT; Hilton F; Hodges MR
    Lancet; 2005 Oct 22-28; 366(9495):1435-42. PubMed ID: 16243088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.
    Viljoen J; Azie N; Schmitt-Hoffmann AH; Ghannoum M
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1671-9. PubMed ID: 25561337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.
    Gebremariam T; Alkhazraji S; Baldin C; Kovanda L; Wiederhold NP; Ibrahim AS
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei.
    Fisher MA; Shen SH; Haddad J; Tarry WF
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1443-6. PubMed ID: 2554797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.